
Sign up to save your podcasts
Or
In this week’s View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol’s effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hypertension.
Subscribe to Eagle’s Eye View
4.7
127127 ratings
In this week’s View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol’s effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hypertension.
Subscribe to Eagle’s Eye View
129 Listeners
314 Listeners
160 Listeners
861 Listeners
488 Listeners
32 Listeners
269 Listeners
83 Listeners
1,090 Listeners
53 Listeners
39 Listeners
184 Listeners
321 Listeners
411 Listeners
37 Listeners